- Shanghai Nianxing Industrial Co., Ltd
- China
- Product Name: Upadacitinib
- Price: Check
- Purity: 98.0%
- Stocking Period: 10 Day
- Contact: Yang
- Email: sales@echemcloud.com
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Upadacitinib
- Price: ￥916.0/1mg ￥3456.0/10mg ￥2116.0/5mg ￥6916.0/25mg
- Purity: 97.0%
- Stocking Period: 1 Day
- Contact: Liu jia
- Email: 2130147988@qq.com
- DC Chemicals Limited
- China
- Product Name: Upadacitinib
- Price: $550.0/100mg $950.0/250mg $1950.0/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Email: sales@dcchemicals.com
- ShangHai DC Chemicals Co.,Ltd
- China
- Product Name: Upadacitinib
- Price: ￥Inquiry/1g
- Purity: 98.9%
- Stocking Period: 1 Day
- Contact: Tony Lai
- Email: order@dcchemicals.com
- Dayang Chem (Hangzhou) Co., Ltd.
- China
- Product Name: Upadacitinib
- Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
- Purity: 98.0%
- Stocking Period: Inquiry
- Contact: Ms Wang
- Email: enquiry@dycnchem.com
- Henan Tianfu Chemical Co., Ltd.
- China
- Product Name: Upadacitinib
- Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
- Purity: 99.0%
- Stocking Period: Inquiry
- Contact: Anson
- Email: info@tianfuchem.com
1310726-60-3
1310726-60-3 structure
- Name: Upadacitinib
- Chemical Name: upadacitinib
- CAS Number: 1310726-60-3
- Molecular Formula: C17H19F3N6O
- Molecular Weight: 380.368
- Catalog: Signaling Pathways Epigenetics JAK
- Create Date: 2018-09-01 19:16:01
- Modify Date: 2025-08-20 11:23:06
-
Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders.
| Name | upadacitinib |
|---|---|
| Synonyms |
upadacitinib
UNII-4RA0KN46E0 (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)- ABT-494 UNII:4RA0KN46E0 |
| Description | Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM, being developed for the treatment of several autoimmune disorders. |
|---|---|
| Related Catalog | |
| Target |
IC50: 43 nM (JAK1), 200 nM (JAK2)[1] |
| In Vitro | In biochemical assays, Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance)[1].. The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit–risk profile in patients with RA range[2]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H19F3N6O |
| Molecular Weight | 380.368 |
| Exact Mass | 380.157257 |
| LogP | 3.06 |
| Index of Refraction | 1.678 |
| Hazard Codes | Xn |
|---|